|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N03AX09
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:brand
|
gptkb:Lamictal
gptkb:Lamictal_XR
|
|
gptkbp:CASNumber
|
84057-84-1
|
|
gptkbp:category
|
mood stabilizer
antiepileptic drug
triazine anticonvulsant
|
|
gptkbp:chemicalFormula
|
C9H7Cl2N5
|
|
gptkbp:contraindication
|
hypersensitivity to lamotrigine
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:eliminationHalfLife
|
25 hours
|
|
gptkbp:form
|
gptkb:tablet
chewable tablet
extended-release tablet
dispersible tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lamotrigine
|
|
gptkbp:interactsWith
|
gptkb:valproic_acid
gptkb:carbamazepine
oral contraceptives
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:United_Kingdom
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
inhibits glutamate release
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
may increase risk of cleft lip/palate
|
|
gptkbp:prescribes
|
gptkb:Lennox-Gastaut_syndrome
tonic-clonic seizures
partial seizures
|
|
gptkbp:proteinBinding
|
55%
|
|
gptkbp:riskFactor
|
gptkb:Stevens-Johnson_syndrome
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
rash
insomnia
|
|
gptkbp:synonym
|
gptkb:Lamictal
BW430C
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Petit_Mal
gptkb:valproic_acid
|
|
gptkbp:bfsLayer
|
6
|